Delivery Order SPE2DB24D1104-SPE2DB25FXWS8

Award Date 1/22/25
Potential Completion Date 1/23/25
Potential Value $3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $3,421.00, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the supply of JATENZO 237 MG CAPSULE 120S, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of February 13, 2025. It is not designated with any set-aside requirements, indicating it was competed openly....
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $3,282.21, is for the delivery of JATENZO 237 MG CAPSULE 120S, a medical product. This contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,131.87 firm fixed-price delivery order is for the supply of JATENZO 237 MG CAPSULE 120S, a pharmaceutical product. The contract has an ultimate completion date of April 4, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,395.61 Firm Fixed Price Delivery Order is for the supply of JATENZO 237 MG CAPSULE 120S, a pharmaceutical product. The contract has an ultimate completion date of December 13, 2024. AmerisourceBergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award is a delivery order worth $1,131.87 awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of JATENZO 237 MG CAPSULE 120S, a pharmaceutical product. The award has an ultimate completion date of February 27, 2025 and a pricing type of Firm Fixed Price. The contract is not designated as a set-aside. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,209.56, is for the delivery of JATENZO 158 MG CAPSULE 120S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a period of performance through March 10, 2025. The contract is not designated with a set-aside requirement, indicating open competition....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of JATENZO 237 MG CAPSULE 120S. The contract, valued at $2,186.98, is a firm-fixed-price delivery order that runs through December 19, 2024. The award is not designated under any set-aside program. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award, valued at $1,133.79, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and an ultimate completion date of March 13, 2025. The contract covers the procurement of JATENZO 237 MG CAPSULE 120S, a pharmaceutical product, and does not have a set-aside designation. Amerisourcebergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,593.70 firm fixed price delivery order is for the supply of JATENZO 237 MG CAPSULE 120S, a pharmaceutical product. The contract has an ultimate completion date of June 3, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award, valued at $1,263.07, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
  • SPE2DB24D1104
    Indefinite Delivery Contract
  • SPE2DB24D1104-SPE2DB25FXWS8
    Delivery Order

This federal contract award, valued at $3,033.11, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of JATENZO 237 MG CAPSULE 120S, a pharmaceutical product.

The award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/21/25, 9:47 AM